Table 1. Baseline characteristics of study participants.
| Patient ID | Gender (M = Male, F = Female) | Age (years) | Baseline CD4 (cells/µL) | Duration of virological suppression (years) | Regimenc | NNRTI or PI based regimen |
| VOR001 | M | 49.8 | 710 | 5.0b | TDF+3TC+EFV once daily | NNRTI |
| VOR002 | M | 51.2 | 494 | 7.7 | TDF/FTC once daily+NVP twice daily | NNRTI |
| VOR003 | M | 56.6 | 479 | 4.0b | TDF/FTC/EFV once daily | NNRTI |
| VOR004 | M | 40.8 | 725 | 13.4 | ABC/3TC once daily+NVP twice daily | NNRTI |
| VOR006 | F | 41.0 | 743 | 11.0 | TDF/FTC/EFV once daily | NNRTI |
| VOR008 | M | 49.2 | 863 | 5.6 | TDF/FTC/EFV once daily | NNRTI |
| VOR009 | M | 54.9 | 703 | 7.5 | TDF once daily+3TC once daily+NVP twice daily | NNRTI |
| VOR010 | M | 49.3 | 371 | 4.4 | TDF/FTC once daily+NVP twice daily | NNRTI |
| VOR011 | M | 55.6 | 1136 | 7.4 | TDF/FTC/EFV once daily | NNRTI |
| VOR013 | M | 45.0 | 1098 | 5.9b | TDF/FTC+DRV+r once daily | PI |
| VOR014 | M | 43.6 | 717 | 3.5 | TDF/FTC/EFV once daily | NNRTI |
| VOR015 | M | 40.4 | 538 | 3.7 | TDF/FTC/EFV once daily | NNRTI |
| VOR016 | M | 43.2 | 951 | 4.9b | AZT+TDF+LPV+r twice daily | PI |
| VOR017 | M | 47.5 | 1335 | 4.5b | ABC/3TC once daily+NVP once daily | NNRTI |
| VOR018 | M | 48.4 | 561 | 2.7 | ABC/3TC+ATV+r once daily | PI |
| VOR019 | M | 42.9 | 855 | 3.5 | TDF/FTC/EFV once daily | NNRTI |
| VOR020 | M | 45.4 | 694 | 4.0b | ABC/3TC once daily+TDF once daily+DRV+r twice daily+RAL twice daily | PI/INI |
| VOR021 | M | 35.0 | 658 | 3.6 | TDF/FTC+ATV+r once daily | PI |
| VOR022 | M | 52.7 | 1094 | 7.9 | AZT+3TC+LPV+r twice daily | PI |
| VOR023 | M | 53.7 | 727 | 7.5 | TDF/FTC+NVP SR once daily | NNRTI |
| Summary Value a | 19 Male (95%) | 47.9 (43.1–52.0) | 721 (610–907) | 5.0 (3.9–7.5) |
a
Values represent n (% with characteristic) or median (interquartile range).
b
Patient had a single HIV RNA viral load to <200 copies/mL during period of suppression.
c
Antiretroviral agents separated by “/” were fixed dose combination.
“+r” denotes administration of ritonavir.
NOTE: TDF, Tenofovir; 3TC, Lamivudine; FTC, Emtricitabine; EFV, Efavirenz; NVP, Nevirapine; ABC, Abacavir; 3TC, Lamivudine; DRV, Darunavir; RTV, Ritonavir; AZT, Zidovudine; LPV, Lopinavir; RAL, Raltegravir; ATV, Atazanavir; NVP SR Nevirapine (slow release).